The Chippenham-based business has acquired the brands Paludrine, Avloclor and Savarine and said it expects the products to contribute around £1.1m to its turnover.
The initial consideration is being funded from existing cash and bank facilities, including a £2m drawdown from its £20m revolving credit facility. Alliance may pay a further £1m over the next three years to AstraZeneca depending on sales of the brands.
Alliance has also appointed two country managers: Dr Philippe Pasdelou has been appointed country manager for France and Lars Börger has been appointed country manager for Germany, Switzerland and Austria,
The country managers are set to focus on securing acquisitions and licensing opportunities in line with the company’s plan to expand into mainland Europe.
John Dawson, Alliance Pharma chief executive, said: “We are delighted to add these important antimalarial brands to the Alliance portfolio, and at the same time to have appointed such highly experienced executives as Philippe Pasdelou and Lars Börger to spearhead our expansion in mainland Europe.”
Earlier this year, Alliance Pharma issued a profit warning after production of one of its products was suspended.